We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Chemiluminescent Assays Evaluated for Heparin-Induced Antibodies

By LabMedica International staff writers
Posted on 30 Aug 2012
Two recently introduced automated chemiluminescent assays for the detection of antibodies have been evaluated in the diagnosis of heparin-induced thrombocytopenia.

The performance of the two assays was compared with enzyme linked immunosorbent assays (ELISA) heparin-induced antibodies (HIA) tests for immunoglobulins IgG and IgAM. More...


Scientists at Ghent University Hospital (Belgium) collected citrated plasmas from 87 patients with clinical suspicion of heparin-induced thrombocytopenia (HIT) were analyzed with all four assays and with a functional confirmation assay. The Zymutest HIA IgG and HIA IgGAM assays (Aniara; West Chester, OH, USA) are micro-ELISAs, that take over two hours to perform, were used as the standard reference.

The fully automated quantitative chemiluminescent immunoassays, the HemosIL AcuStar HIT-IgG (Platelet Factor 4-Heparin, PF4-H), specific for IgG anti-PF4/H antibodies, and the HemosIL AcuStar HIT-Ab (PF4-H), detecting IgG, IgM and IgA anti-PF4/H antibodies are products of Instrumentation Laboratory (Bedford, MA, USA). They provide enhanced detection of HIT antibodies in specialty and hospital hemostasis laboratories. Unlike existing manual processes, the ready-to-use, cartridge-based assays offer results in approximately 30 minutes.

The sensitivities of all assays were 100%. The Acustar HIT-IgG assay showed 85% specificity compared to the 73% for the HIT-Ab assay using the manufacturer’s cutoffs. Specificities of all assays, except for the AcuStar HIT-IgG, could be significantly improved when altering the cutoff. Titers were significantly higher for the HIT-Ab assay compared with the HIT-IgG assay. This was also the case for the patients with confirmed HIT indicating that the cutoff of 1.0 Optical Density (OD) for both AcuStar assays, as proposed by the manufacturer, can be adapted for the AcuStar Hit-Ab assay resulting in an increased specificity.

Chemiluminescent technology provides analytical excellence through an expansive working range for high sensitivity and precision allowing clinicians to make timely, well-informed therapeutic decisions. In addition, the Acustar HIT precalibrated reagent cartridges offer significant time- and cost- efficiencies. The study was published in the August 2012 edition of the International Journal of Laboratory Hematology.

Related Links:

Ghent University Hospital
Aniara
Instrumentation Laboratory



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.